ライフサイエンスコーパス: PLA2

1 ived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

2 ciation and subsequent enzymatic reaction of PLA2.

3 responses are dependent on CD1a protein and PLA2.

4 na benthamiana via recombinant expression of PLA2.

5 A2alpha (cPLA2alpha) or calcium-independent PLA2.

6 five percent of participants had abnormal Lp-PLA2.

7 future challenge with a near-lethal dose of PLA2.

8 y response in part by effects elicited by Lp-PLA2.

9 3) complexes with a wide range of mutants of PLA2.

10 allosteric states of the interface activated PLA2.

11 ng of the sulfate head group in contact with PLA2.

12 s is characterized by local production of Lp-PLA2.

13 intracellular PLA2, the calcium-independent PLA2.

14 inhibitors for group VIA calcium-independent PLA2.

15 d substantially long dissociation rates from PLA2.

16 (20-30 min post-P4) rely on group X secreted PLA2.

17 apoB, only prava40 led to a reduction in Lp-PLA2 (-15%, p = 0.008) and atorva10 to a decrease in OxL

18 g/dL) below the cut-off value of circulating PLA2 (2.07 nM, equivalent to 290 ng/dL) present in serum

19 BI)-induced neuroinflammation via activating PLA2/5-LOX/LTB4 cascade using a partial frontal lobe res

20 nd improves outcomes after SBI by activating PLA2/5-LOX/LTB4 cascade.

21 spholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is an important inflammatory signa

22 k of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target.

23 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enzyme

24 rapy significantly decreased the level of Lp-PLA2, a vascular-specific, inflammatory enzyme that pred

25 ing that bee venom-derived phospholipase A2 (PLA2) activates T cells through generation of small neoa

26 monstrated that the P2X7 receptor can induce PLA2 activation and arachidonic acid mobilization.

27 of these factors to the complex kinetics of PLA2 activation are not well understood.

28 tes competitively inhibited the thrombin and PLA2 activities.

29 LA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross-se

30 PLA2 activity (MJ33 sensitive) in cell lysates following

31 nd PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race, se

32 Here, we used pressure modulation of the PLA2 activity and of the membrane's physical-chemical pr

33 e to develop a versatile assay that monitors PLA2 activity based on interactions with natural phospho

34 Lp-PLA2 activity correlated with several CHD risk markers.

35 PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationship i

36 lly be used as nanosensors for monitoring of PLA2 activity in biological samples with minimal sample

37 s that the previously reported difference in PLA2 activity in CSF samples from healthy and AD individ

38 ma (iPLA2gamma) accounts for the majority of PLA2 activity in rabbit ventricular myocytes and is resp

39 The total PLA2 activity in sonicated platelets was diminished, and

40 PLA2 activity of recombinant phosphoPrdx6 was decreased

41 m patatin-like phospholipase (PfPATPL1) with PLA2 activity plays a key role in gametogenesis.

42 Adding Lp-PLA2 activity tertiles to the model improved the predict

43 e of exosomes, which transferred cytoplasmic PLA2 activity to neighboring CD1a-expressing cells.

44 ine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and risk

45 nts for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.31 t

46 ariants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular ri

47 phox) binds to phosphoPrdx6 and inhibits its PLA2 activity, an interaction that could function to ter

48 ER stress, and NOXA, but not the increase in PLA2 activity, indicating that PLA2 is upstream of these

49 Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest ef

50 tic effects of the lipid phase transition on PLA2 activity, the membrane insertion depth of PLA2 incr

51 f lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization of v

52 9V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher activ

53 correlate with their selective inhibition of PLA2 activity.

54 tion, immunohistochemistry, and enzymatic Lp-PLA2 activity.

55 sk Score tertile had significantly higher Lp-PLA2 activity.

56 nance (MR) imaging contrast agent to monitor PLA2 activity.

57 various diseases associated with an elevated PLA2 activity.

58 Phospholipase A2 (PLA2) activity has been shown to be involved in the sper

59 lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of coro

60 patatin-like proteins have phospholipase A2 (PLA2) activity, recombinant TgPL1 purified from Escheric

61 sitively characterised for phospholipase A2 (PLA2) activity, suggesting their plausible involvement i

62 been developed to monitor phospholipase A2 (PLA2) activity.

63 The phospholipase A2 (PLA2)activity of phosphorylated peroxiredoxin 6 (Prdx6)

64 Lp-PLA2, also known as platelet-activating factor acetylhyd

65 tivity of Ca(2+)-dependent phospholipase A2 (PLA2), an inflammatory protein that (i) plays a role in

66 Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipids t

67 tically inert stoichiometric complex between PLA2 and any bile salts in which it forms a stable compl

68 ehavior that is comparable to that of native PLA2 and DeltaPLA2 with a deleted 62-66 loop.

69 Therefore, PLA2 and ENPP6 activities may represent a key step in th

70 PLA2 and ENPP6 may act in concert to generate phosphocho

71 Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6 levels, smaller increases in total cholest

72 This study has investigated whether Lp-PLA2 and its major enzymatic product, lysophosphatidylch

73 The Lp-PLA2 and OxLDL were reduced in statin-treated groups, bu

74 The strongest inhibitory activities toward PLA2 and TG were found in the hydrolysates obtained by h

75 ED, phospholipase C (PLC), phospholipase A2 (PLA2) and a mixture of phospholipases Purifine 3G (3G) w

76 we propose that 2 enzymes-phospholipase A2 (PLA2) and ectonucleotide pyrophophatase/phosphodiesteras

77 e investigated the role of phospholipase A2 (PLA2) and the effects of PLA2 products (polyunsaturated

78 ost similar to mammalian calcium-independent PLA2, and additionally contains leucine-rich repeats and

79 orm technology for a safe and effective anti-PLA2 approach.

80 whereas both iPLA2beta and group X secreted PLA2 are involved in P4-induced AR.

81 57-72 loop and the H(48)DNCY(52) segment of PLA2 are involved in transmitting the effect of the coop

82 Interestingly, candidate genes in pla1 and pla2 are themselves related by an older duplication.

83 lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and dem

84 Phospholipase A2 enzymes (PLA2) are known to mediate membrane remodeling and vesic

85 ues to build supporting the usefulness of Lp PLA2 as a predictor of coronary events in the general po

86 ts, an elicitor-responsive phospholipase A2 (PLA2) at the plasma membrane generates signal molecules

87 Melittin acts as a PLA2 attractant that works together with the membrane li

88 Lp-PLA2 augments the inflammatory response after MI and ant

89 The five PLA2-bile salt complexes each result in a partly occlude

90 The results show that PLA2 binding to model biomembranes is not significantly

91 e by preferentially inducing the activity of PLA2 but not LPCAT in human and mouse SCD erythrocytes.

92 ivated protein kinase) and phospholipase A2 (PLA2), but its action is independent of phosphoinositide

93 when HDL was destabilized in the presence of PLA2 by the action of cholesteryl ester transfer protein

94 enhanced binding and activation of the bound PLA2 by the bile salt induced anionic charge in a zwitte

95 mplex of pig pancreatic IB phospholipase A2 (PLA2) can be considered a proxy for interface-activated

96 We evaluated the association between Lp-PLA2, cardiac allograft vasculopathy (CAV) assessed by 3

97 lts and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical athe

98 Phospholipases A2 (PLA2) catalyze the hydrolysis reaction of sn-2 fatty aci

99 ions of a biphasic dependence of the rate of PLA2 catalyzed hydrolysis of zwitterionic glycerophospho

100 that lipid enzymes such as phospholipase A2 (PLA2) contain allosteric activator sites for specific ph

101 her work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD.

102 disulfide linkages of several cytotoxins and PLA2 could be solved, including more than 20 disulfide b

103 thermore, we showed that the IgE response to PLA2 could protect mice from future challenge with a nea

104 ic activity of membrane-associated bee venom PLA2, covering a pressure range up to 2 kbar.

105 The group IVA cytosolic isoform of PLA2 (cPLA2alpha) was activated upon S. pneumoniae infec

106 the inflammatory process: phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2), thrombin, and transglut

107 aglandin synthesis through the activation of PLA2, cyclooxygenases (COX-1 and -2) and prostaglandins

108 As a specific inhibitor of Lp-PLA2, darapladib has been shown to be protective against

109 levels; factors associated with a larger Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6

110 whose bone marrow-derived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

111 Phospholipase A2 (PLA2)-dependent pathways are important in the regulation

112 tivate the enzyme group-IB phospholipase A2 (PLA2) derived from the pancreas.

113 RECENT FINDINGS: The group 1B PLA2 digestion of phospholipids in the intestinal lumen

114 The 3D homology model of each PLA2 displays a binding pocket that specifically accommo

115 r and amphiphilic lipids differed for WD and PLA2 ED vs PLC and 3G ED.

116 in the liposomal membrane were hydrolyzed by PLA2, encapsulated Gd was released into bulk solution, r

117 We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAVD a

118 ib is an oral, selective inhibitor of the Lp-PLA2 enzyme.

119 PLA2 enzymes are an important pharmacological target imp

120 s showing distinct roles of several of these PLA2 enzymes in inflammatory metabolic diseases such as

121 cific drugs that target one or more of these PLA2 enzymes may be novel strategies for treatment of th

122 their binding mode with two human cytosolic PLA2 enzymes: group IVA cPLA2 and group VIA iPLA2.

123 Phospholipase A2 (PLA2) enzymes act at the membrane-water interface to acc

124 Phospholipase A2 (PLA2) enzymes, which catalyze the hydrolysis of phosphol

125 dividuals originates from differences in the PLA2 expression level rather than from the enzyme activi

126 Each member of the PLA2 family of enzymes serves a distinct role in generat

127 PURPOSE OF REVIEW: The phospholipase A2 (PLA2) family of proteins includes lipolytic enzymes that

128 with the membrane lipids to "lure" in-coming PLA2 for attack.

129 Pig pancreatic IB phospholipase A 2 (PLA2) forms three distinguishable premicellar E i (#) (

130 The rapid evolution of PLA2 gene number appears to be due to transposon invasio

131 in and evolution of PLA2 toxins by examining PLA2 gene number, organization, and expression in both n

132 Patient studies showed that injected PLA2 generates lysophospholipids within human skin in vi

133 been tested with the human Group V secreted PLA2 (GV sPLA2) and the human Group VIA calcium-independ

134 and the human Group VIA calcium-independent PLA2 (GVIA iPLA2).

135 The products of PLA2 had opposing effects on TRPM8.

136 Selective inhibition of Lp-PLA2 has been postulated to reduce necrotic core progres

137 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogene

138 Inhibition of phospholipase A2 (PLA2) has long been considered for treating various dise

139 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-density lipoproteins into

140 conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV)-i

141 confirm or refute a contributory role for Lp-PLA2 in CHD.

142 have data emerged demonstrating a role of Lp-PLA2 in development of advanced coronary artery disease.

143 a (cPLA2alpha) is thought to be the dominant PLA2 in eosinophils; however, eosinophils also have secr

144 This study tested the role of Lp-PLA2 in healing after MI.

145 furthering our understanding of the role of PLA2 in health and disease and in detecting the pharmaco

146 e release of AA, we investigated the role of PLA2 in local and systemic disease during S. pneumoniae

147 A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors.

148 Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quantita

149 These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammation

150 the catalytic activity of phospholipase A2 (PLA2) in both pure and complex biological fluids.

151 lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD).

152 s of the allergen Api m 1 (phospholipase A2: PLA2) in HBV.

153 A2 activity, the membrane insertion depth of PLA2 increases only modestly above Tm.

154 We found that bee venom PLA2 induced a T helper type 2 (Th2) cell-type response

155 In the study, L&K-NPs effectively inhibit PLA2-induced hemolysis.

156 les a "lure and kill" mechanism designed for PLA2 inhibition (denoted "L&K-NP").

157 en together, this study demonstrates that Lp-PLA2 inhibition can effectively prevent diabetes-mediate

158 definitive proof, of a potential role for Lp PLA2 inhibition in coronary heart disease prevention.

159 The findings suggest that PLA2 inhibition or CD1a blockade may have therapeutic po

160 Systemic Lp-PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) effec

161 Administration of Manoalide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC r

162 Pretreatment with the PLA2 inhibitor, aristolochic acid, abrogated the increas

163 on the efficacy of darapladib, a specific Lp PLA2 inhibitor, show beneficial changes in plaque morpho

164 (i.c.v) with mepacrine [a phospholipase A2 (PLA2) inhibitor], ibuprofen [a nonselective COX inhibito

165 X in eicosanoid formation was examined using PLA2 inhibitors and murine tracheal epithelial cells wit

166 effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contri

167 However, safe and effective PLA2 inhibitors remain unavailable.

168 Understanding how PLA2 inhibits lipid oxidation promoted by hemoglobin (Hb

169 r cells by inhibition of calcium-independent PLA2 (iPLA2).

170 Elevated Lp PLA2 is also associated with stroke and heart failure.

171 othesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary atheros

172 Lp PLA2 is gaining acceptance as a useful biomarker of chro

173 Lp-PLA2 is highly abnormal in HIV-infected patients and is

174 Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role in

175 Lp-PLA2 is independently associated with progression of CAV

176 ular and biochemical nature of intracellular PLA2 is not well understood in plants.

177 The crystal structure of Lp PLA2 is now available and offers insight into the links

178 Here we examined how bee venom PLA2 is sensed by the innate immune system and induces a

179 e increase in PLA2 activity, indicating that PLA2 is upstream of these events.

180 Phospholipase A2 (PLA2) is a conserved component of venoms from multiple s

181 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular infl

182 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary artery disease (CAD)

183 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular disease

184 In addition, phospholipase A2 (PLA2) is highly expressed in psoriatic lesions and is kn

185 elopment of inhibitors for phospholipase A2 (PLA2) is important in elucidating the enzymes implicatio

186 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key position in the path

187 A phospholipase A2 (PLA2) is thought to be involved in the acyl-editing proc

188 hosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction.

189 reaction (AR), but the molecular identity of PLA2 isoforms has remained elusive.

190 scular regulators, but the phospholipase A2 (PLA2) isoforms supporting their production within the ca

191 administered with a lethal dose of venomous PLA2, L&K-NPs also inhibit hemolysis and confer a signif

192 SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP.

193 High Lp-PLA2 level was associated with increase in plaque volume

194 Lp-PLA2 level>236 ng/mL (higher tertile) identified a subgr

195 y significant predictors of a decrease in Lp-PLA2 level.

196 ion independently predicted the change in Lp-PLA2 level.

197 lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin group, compared with

198 Elevated Lp-PLA2 levels associate with increased risk of cardiovascu

199 Lp-PLA2 levels correlate with an increased risk of recurren

200 In response to MI, Lp-PLA2 levels markedly increased in the circulation.

201 The Lp-PLA2 levels positively correlated with age (r = 0.09), b

202 Elevated Lp-PLA2 levels predict CHD events in apparently healthy old

203 Arterial Lp-PLA2 levels were similar in patients and control subject

204 to greater decreases in sCD14, hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

205 re noted for changes in sCD14, hsCRP, and Lp-PLA2 levels.

206 in HIV-infected individuals by decreasing Lp-PLA2 levels.

207 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease (CH

208 red with the Poaceae vascular plants TE1 and PLA2/LHD2 mutants.

209 .19, P=0.012) compared with patients with Lp-PLA2< or =236 ng/mL.

210 n, incubating cells with the two products of PLA2 (lysophosphatidic acid and arachidonic acid) mimick

211 -based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-nai

212 intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity.

213 CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calcium

214 Mean Lp-PLA2 mass was 313 +/- 105 ng/mL and activity 173 +/- 49

215 lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associated with an increased r

216 Lp-PLA2 may be a useful marker for risk of CAV and a therap

217 Thus, Lp-PLA2 may be a useful therapeutic target for patients wit

218 Indeed, Lp-PLA2 may be an important link between lipid homeostasis

219 Lp-PLA2 may be used as an additional and more vascular spec

220 notherapy, the therapeutic administration of PLA2-MB treatment to mice that already had established a

221 To identify unknown PLA2-mediated activities on the molecular components of

222 raction that could function to terminate the PLA2-mediated NOX2 activation signal.

223 ifferent mechanism from the Ca(2+)-dependent PLA2-mediated phospholipid hydrolysis.

224 lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL) with antibody 4E6,

225 he later, reparative phase, infarcts of bmLp-PLA2 (-/-) mice contained Ly-6C(low) macrophages with a

226 Accordingly, bmLp-PLA2 (-/-) mice developed smaller and less inflamed infa

227 Consequently, the hearts of bmLp-PLA2 (-/-) mice healed more efficiently, as determined b

228 Compared with wild-type controls, bmLp-PLA2 (-/-) mice subjected to MI had lower serum levels o

229 Cs required Prdx6-PLA2 We propose that Prdx6-PLA2 modulates NOX2 activation by generation of LPC that

230 Thus, Prdx6-PLA2 modulates NOX2 activation through generation of LPC

231 rattlesnakes ( approximately 6 mya), while a PLA2 myotoxin gene retained in C. atrox was deleted from

232 Lp-PLA2 net production in the coronary circulation was high

233 is hence markedly affected by HHP, rendering PLA2, next to being a primary osmosensor, a good candida

234 spitting cobra) venom contains 15% secretory PLA2 of its dry weight.

235 ice that lack the phospholipase A2 activity (PLA2) of Prdx6; addition of either lysophosphatidylcholi

236 t of the other class; for example, C. roseus PLA2 only accommodates C. roseus alkaloids.

237 Blocking ABC transporter, PLA2 or 12-Lox activity also inhibits homing of germ cel

238 ro In addition, inhibiting phospholipase A2 (PLA2) or lipoxygenase (Lox) blocks chemotaxis towards lo

239 optimized NP showed selectivity for venomous PLA2 over abundant serum proteins, was not cytotoxic, an

240 fferent sperm subpopulations, using distinct PLA2 pathways to achieve AR.

241 a role in gametogenesis, thereby identifying PLA2 phospholipases such as PfPATPL1 as potential target

242 in establishing drug tolerance by regulating PLA2/PKCalpha activity and reactive oxygen species.

243 udy, we observed expression of a cytoplasmic PLA2 (PLA2G4D) in psoriatic mast cells but, unexpectedly

244 Intracellular phospholipase A2 (PLA2) plays an important role in regulating oxylipin bio

245 the proteolytic and lipolytic activities of PLA2 proceed through different mechanisms.

246 f phospholipase A2 (PLA2) and the effects of PLA2 products (polyunsaturated fatty acids and lysophosp

247 enge with S. pneumoniae As phospholipase A2 (PLA2) promotes the release of AA, we investigated the ro

248 mice that already had established allergy to PLA2 protects all subsequently challenged animals.

249 erized the protein and lipid products of the PLA2 reaction with HDL.

250 oform (pla2g4a), iPLA2 isoform (pla2g6), and PLA2-receptor (pla2r1) were present in all tissues of bo

251 studies, hydrolysis of HDL phospholipids by PLA2 reduced the particle size without changing its prot

252 Selective inhibition of Lp-PLA2 reduces development of necrotic cores and may resul

253 containing signaling molecules; for example, PLA2 regulates the generation of precursors for the bios

254 Among snakes, phospholipase A2 (PLA2)-related toxins have evolved in different lineages

255 Results indicated that PLA2 required calcium ion for both the hydrolyzing activ

256 mentation maps to a genomic region (pla1 and pla2, respectively) containing adjacent, apparently rece

257 erve as the messengers downstream of DGK and PLA2, respectively.

258 nges were SAA (serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhy

259 e (NMR) and other complementary results with PLA2 show that decylsulfate molecules in E 2 (#) and E 3

260 tophagy gene ATG5 Accordingly, inhibition of PLA2 significantly decreased lipid droplets, decreased o

261 Inhibition of PLA2 similarly abolished the cold responses of the major

262 containing 20% palmitic acid and PEG induced PLA2-specific IgA and increased Foxp3(+) Treg frequencie

263 ils; however, eosinophils also have secreted PLA2 (sPLA2) activity that has not been fully defined.

264 limit of detection (LOD) of human secretory PLA2 (sPLA2) in up to 1000-fold-diluted cerebrospinal fl

265 nd human studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by

266 In contrast to conventional PLA2 subcutaneous immunotherapy, the therapeutic adminis

267 f these methods require the use of unnatural PLA2 substrates that may alter enzyme kinetics, and prob

268 reorganization of alpha-helical segments of PLA2 takes place at the lipid water interface.

269 in detecting the pharmacodynamic effects of PLA2-targeting drug candidates.

270 ic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhibits a marked preference for hydrolysis of

271 a previously unknown proteolytic activity of PLA2 that is specific to apoA-I and may contribute to th

272 olipase A2 (cPLA2 ), an important isoform of PLA2 that mediates the release of arachidonic acid, play

273 tially inhibit the other major intracellular PLA2, the calcium-independent PLA2.

274 Mice were challenged with a lethal dose of PLA2 to evaluate protection against anaphylaxis.

275 The abilities of PLA2 to inhibit lipid oxidation and suppress oxidation o

276 dose, pH, and calcium ion on the ability of PLA2 to inhibit trout hemoglobin-mediated lipid oxidatio

277 he micellar complex formed by the binding of PLA2 to preformed micelles.

278 as critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids and free fatty acids

279 e traced the genomic origin and evolution of PLA2 toxins by examining PLA2 gene number, organization,

280 The number of Lp-PLA2 transcripts correlated with several indexes of tiss

281 anwhile, OOPC acts as inhibitor that "kills" PLA2 upon enzymatic attack.

282 However, PLA2 was able to inhibit lipid oxidation without prevent

283 Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% on h

284 ApoA-I proteolysis by PLA2 was Ca(2+)-independent, implicating a different mec

285 onmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic val

286 Lp-PLA2 was measured in plasma aliquots using an enzyme-lin

287 fect of porcine pancreatic phospholipase A2 (PLA2) was previously demonstrated.

288 e generation of LPC by PMVECs required Prdx6-PLA2 We propose that Prdx6-PLA2 modulates NOX2 activatio

289 and neutralizing venomous phospholipase A2 (PLA2), we demonstrate that broad-spectrum neutralization

290 To test the functional importance of Lp-PLA2, we generated chimeric mice whose bone marrow-deriv

291 (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

292 idly increased activity of phospholipase A2 (PLA2), which led to an increase in cytoplasmic calcium,

293 subsequent inactivation of phospholipase A2 (PLA2), whose metabolites are known to modulate ion chann

294 , suggesting specific and direct reaction of PLA2 with apoA-I.

295 ienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy an

296 ted that RcsPLA2alpha functions in vivo as a PLA2 with HFA specificity.

297 used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina, o

298 Incubation of PLA2 with lipid-free apoA-I produced similar protein fra

299 al structures of the complexes of pancreatic PLA2 with the naturally occurring bile salts: cholate, g

300 The amphipathic bile salts are bound to PLA2 with their polar hydroxyl and sulfate/carboxy group